Affiliation:
1. The First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang 150036, China
2. Chinese Medicine Research Institute, Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang
150040, China
3. Heilongjiang Academy of Traditional Chinese Medicine, Harbin, Heilongjiang 150040, China
Abstract
Aims:
Syringopicroside (SYR) is an iridoid monomer compound isolated from the
leaves of clove. HBV is a hepatotropic virus that can cause severe liver diseases, including acute
and chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). Syringopicroside has a significant
effect on anti-HBV, but its mechanism of action is still unclear.
Methods:
A metabolomics approach based on UPLC-G2-Si-HDMS was performed to analyze the
serum biomarkers from HBV transgenic mice to find the biomarkers affected by syringopicroside.
Through the analysis of metabolic pathways, the key pathways of syringopicroside involved
in a therapeutic action were explored to study its potential mechanism. Using network pharmacology,
the "component-target-pathway" network of syringopicroside in the treatment of hepatitis
B was constructed and combined with the results of metabolomics. Furthermore, the mechanism
of action of syringopicroside against HBV was also discussed.
Results:
Serum metabolomics identified a total of 42 HBV-related biomarkers, of which 8 returned
to normal levels after syringopicroside treatment, involving a total of 6 metabolic pathways.
Five biomarkers returned to normal levels after lamivudine treatment, involving 2 metabolic
pathways. Network pharmacology analysis showed that syringopicroside in the treatment of
hepatitis B mainly acts on 26 targets, including MMP9, MAPK1, and SLC29A1, involving 4
pathways.
Conclusion:
This study elucidates the multi-target and multi-channel integration mechanism of
syringopicroside against HBV, lays a foundation for an in-depth study of the anti-HBV mechanism
of syringopicroside, and also provides support for the development of innovative traditional
Chinese medicines for the treatment of hepatitis B.
Funder
National Natural Science Foundation of China
Heilongjiang Province Postdoctoral Special Fund
Heilongjiang Province Postdoctoral Research Foundation
Heilongjiang Provincial Natural Science Foundation Project
Heilongjiang University of Traditional Chinese Medicine Foundation Project
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmaceutical Science,Molecular Medicine,Biochemistry,Biophysics